Equities research analysts expect that Nabriva Therapeutics PLC – (NASDAQ:NBRV) will report sales of $1.23 million for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Nabriva Therapeutics’ earnings. The highest sales estimate is $2.62 million and the lowest is $500,000.00. Nabriva Therapeutics posted sales of $460,000.00 in the same quarter last year, which would indicate a positive year over year growth rate of 167.4%. The firm is expected to announce its next earnings report on Tuesday, November 5th.
According to Zacks, analysts expect that Nabriva Therapeutics will report full-year sales of $6.94 million for the current year, with estimates ranging from $3.38 million to $11.98 million. For the next fiscal year, analysts expect that the business will report sales of $30.83 million, with estimates ranging from $21.00 million to $39.69 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Nabriva Therapeutics.
Nabriva Therapeutics (NASDAQ:NBRV) last posted its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.04. The company had revenue of $0.53 million for the quarter, compared to analysts’ expectations of $0.88 million. Nabriva Therapeutics had a negative net margin of 3,602.24% and a negative return on equity of 139.52%.
In other Nabriva Therapeutics news, CEO Theodore R. Schroeder bought 50,000 shares of the stock in a transaction on Tuesday, August 27th. The shares were acquired at an average price of $1.79 per share, with a total value of $89,500.00. Following the acquisition, the chief executive officer now directly owns 5,786 shares of the company’s stock, valued at approximately $10,356.94. The transaction was disclosed in a document filed with the SEC, which is available through this link. In the last three months, insiders have acquired 64,977 shares of company stock worth $119,951 and have sold 21,773 shares worth $45,186. Insiders own 3.32% of the company’s stock.
Hedge funds have recently modified their holdings of the business. A.R.T. Advisors LLC bought a new stake in Nabriva Therapeutics during the 2nd quarter valued at $90,000. Parametric Portfolio Associates LLC raised its holdings in Nabriva Therapeutics by 180.8% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 52,272 shares of the biotechnology company’s stock valued at $127,000 after acquiring an additional 33,656 shares during the period. Commonwealth Equity Services LLC raised its holdings in Nabriva Therapeutics by 30.0% during the 2nd quarter. Commonwealth Equity Services LLC now owns 65,010 shares of the biotechnology company’s stock valued at $157,000 after acquiring an additional 15,000 shares during the period. Wells Fargo & Company MN bought a new stake in Nabriva Therapeutics during the 2nd quarter valued at $169,000. Finally, Morgan Stanley raised its holdings in Nabriva Therapeutics by 52.9% during the 2nd quarter. Morgan Stanley now owns 265,418 shares of the biotechnology company’s stock valued at $645,000 after acquiring an additional 91,869 shares during the period. 3.89% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ:NBRV traded up $0.02 during mid-day trading on Friday, reaching $1.89. The company had a trading volume of 808,955 shares, compared to its average volume of 1,155,002. The company has a current ratio of 5.67, a quick ratio of 5.67 and a debt-to-equity ratio of 0.56. The firm has a market cap of $1.39 billion, a price-to-earnings ratio of -1.16 and a beta of 2.43. The company’s 50-day moving average price is $2.13 and its 200-day moving average price is $2.38. Nabriva Therapeutics has a one year low of $1.12 and a one year high of $3.27.
About Nabriva Therapeutics
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
Read More: Calculate Your Return on Investment (ROI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.